Telix has entered into an agreement to commercially partner the QDOSE dosimetry software platform with Germany-based contract research organisation Advanced Pharmaceutical Services Forschungsgesellschaft and its partner, Stockholm-based Quantinm.
-
Latest News Telix announces QDOSE platform partnership for personalised dosimetry in radiopharmaceutical the March 19, 2024
-
Latest News Cyclopharm says milestone achieved with first US patients imaged with Technegas March 19, 2024The company said these events follow the US FDA approval of Technegas last October and the subsequent rollout of its plan for market penetration in medical facilities across the US.
-
Latest News Dimerix raises $20 million to continue and expand late-stage clinical trial of DMX-200 March 14, 2024Dimerix (ASX:DXB) has announced it has received firm commitments to raise $20 million via an institutional placement with proceeds to complete the ACTION3 Phase 3 clinical study in patients with debilitating kidney disease.
-
AusBiotech AusBiotech appoints new Board Observer March 14, 2024AusBiotech’s Board of Directors welcomes Kingsford Smith, VP, Medical Affairs, Market Access & Government Affairs, Cochlear, as Board Observer.
-
Latest News Neurotech International announces extension of NTI164 in female Rett Syndrome March 14, 2024Neurotech International (ASX:NTI) has announced the extension of its Phase 1/2 clinical trial investigating the use of NTI164 in female Rett Syndrome patients and an additional ethics approval.
-
Latest News Althea Group welcomes French plan to legalise medicinal cannabis extracts March 14, 2024Medicines cannabis company Althea Group Holdings (ASX:AGH) has updated on developments in France’s generalisation of the use of related products.
-
Snow Medical Research Foundation announces grant for UQ genetic researchers March 12, 2024Snow Medical Research Foundation has awarded University of Queensland researchers $8 million to advance the use of genomics to prevent chronic diseases such as type 2 diabetes, heart disease and Alzheimer’s.
-
AusBiotech AusBiotech launches ASX feed March 12, 2024A life science-specific Australian Stock Exchange (ASX) data feed has been launched on AusBiotech’s website to increase the profile of and investment in Australia’s biotechnology companies.
-
Latest News Mesoblast says US FDA feedback indicates support for accelerated approval pathway March 12, 2024Australian cell medicine company Mesoblast (ASX:MSB) has announced that the US FDA supported an accelerated approval pathway for the company's rexlemestrocel-L.
-
Latest News Imricor says Paris-based CV institute grants ethics approval for VISABL-AFL trial March 12, 2024Imricor’s Chair and CEO, Steve Wedan, said, “After last week’s announcement regarding Ethics Committee approval at the CHUV in Lausanne, we are very excited to announce that the Ethics Committee at ICPS has followed so quickly."
-
Latest News Anteris Technologies welcomes updated DurAVR THV for serious heart condition March 12, 2024The company said the data builds on the positive clinical results reported to date which demonstrate this new class of biomimetic valve outperforms the market leader, returning patients to a near normal blood flow state.
-
Latest News Nyrada successfully raises $1.755 million to support the development of NYR-BI03 March 7, 2024Nyrada (ASX:NYR) has received firm commitments for a placement of 23.4 million Chess Depository Instruments (CDIs), raising $1,755,000 in new equity capital from new and existing professional and sophisticated investors.
-
AusBiotech ‘Innovations in equality’ highlighted on International Women’s Day March 7, 2024More than 650 life science professionals will gather tomorrow for AusBiotech’s annual NSW Women in Life Sciences Luncheon to examine the pathways to greater economic inclusion for women in biotechnology.
-
Latest News Clarity Pharmaceuticals says SAR-bisPSMA detects PC lesions in the 2-millimetre range March 7, 2024Clinical-stage radiopharmaceutical company Clarity Pharmaceuticals (ASX:CU6) has shared additional data from its diagnostic Cu-SAR-bisPSMA trial, COBRA.
-
Latest News AdAlta announces positive results from Phase 1 extension study of lead asset AD-214 March 7, 2024AdAlta (ASX:1AD) has announced results from its Phase 1 extension study of lead asset AD-214 in development for fibrotic diseases, including the debilitating and fatal disease Idiopathic Pulmonary Fibrosis.
-
Latest News Proteomics International retains its ISO 13485 certification March 7, 2024Predictive diagnostics company Proteomics International Laboratories (ASX:PIQ) has successfully retained its ISO 13485 certification, an internationally recognised standard for safety and quality management systems in the manufacture of medical devices.
New Stories
-
Queensland’s biomedical grant programme opens
March 19, 2024 - - AusBiotech -
Cyclopharm says milestone achieved with first US patients imaged with Technegas
March 19, 2024 - - Latest News -
Telix announces QDOSE platform partnership for personalised dosimetry in radiopharmaceutical the
March 19, 2024 - - Latest News -
PYC Therapeutics announces the completion of institutional placement
March 19, 2024 - - Latest News -
CSIRO announces the appointment of new Australian Centre for Disease Preparedness director
March 19, 2024 - - Latest News -
AusBiotech appoints new Board Observer
March 14, 2024 - - AusBiotech -
Neurotech International announces extension of NTI164 in female Rett Syndrome
March 14, 2024 - - Latest News